MICHAEL VINCEN-BROWN: Open Payments
NPI 1003326398 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$90 in 5 payments from 4 companies in 2025. Trend: 2023 $191 · 2024 $55 · 2025 $90
Food & beverage: $90
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: RECORLEV, Ozempic, SHINGRIX, FARXIGA.
Industry payments across ID — which companies pay providers there.
